Marina Biotech Completes Dosing of Second Cohort in the Phase 1b START-FAP Clinical Trial of CEQ508

BOTHELL, WA, Apr 03, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-baseddrug discovery and development company, today announced thecompletion of dosing for Cohort 2 in the Dose Escalation Phase of itsSTART-FAP (Safety and Tolerability of An RNAi Therapeutic in FamilialAdenomatous Polyposis) clinical trial with CEQ508. The three patientsof Cohort 2 received a dose of 1x10(9) colony forming units (cfu)/dayfor up to 28 days of continuous oral dosing. Patients were monitoredby study staff on a daily basis with the primary study endpoint ofdetermining safety and tolerability of CEQ508 in patients with FAP.Dosing of Cohort 3 is expected...